395 related articles for article (PubMed ID: 29780321)
1. Toll-Like Receptor 2 Signaling and Current Approaches for Therapeutic Modulation in Synucleinopathies.
Caplan IF; Maguire-Zeiss KA
Front Pharmacol; 2018; 9():417. PubMed ID: 29780321
[TBL] [Abstract][Full Text] [Related]
2. Toll-like receptors and their therapeutic potential in Parkinson's disease and α-synucleinopathies.
Kouli A; Horne CB; Williams-Gray CH
Brain Behav Immun; 2019 Oct; 81():41-51. PubMed ID: 31271873
[TBL] [Abstract][Full Text] [Related]
3. Innate immunity and neuroinflammation in the CNS: the role of microglia in Toll-like receptor-mediated neuronal injury.
Lehnardt S
Glia; 2010 Feb; 58(3):253-63. PubMed ID: 19705460
[TBL] [Abstract][Full Text] [Related]
4. Targeting toll-like receptor 4 to modulate neuroinflammation in central nervous system disorders.
Leitner GR; Wenzel TJ; Marshall N; Gates EJ; Klegeris A
Expert Opin Ther Targets; 2019 Oct; 23(10):865-882. PubMed ID: 31580163
[No Abstract] [Full Text] [Related]
5. Non-cell-autonomous Neurotoxicity of α-synuclein Through Microglial Toll-like Receptor 2.
Kim C; Lee HJ; Masliah E; Lee SJ
Exp Neurobiol; 2016 Jun; 25(3):113-9. PubMed ID: 27358579
[TBL] [Abstract][Full Text] [Related]
6. Targeting Microglial and Neuronal Toll-like Receptor 2 in Synucleinopathies.
Kwon S; Iba M; Masliah E; Kim C
Exp Neurobiol; 2019 Oct; 28(5):547-553. PubMed ID: 31698547
[TBL] [Abstract][Full Text] [Related]
7. Differential role of Dok1 and Dok2 in TLR2-induced inflammatory signaling in glia.
Downer EJ; Johnston DG; Lynch MA
Mol Cell Neurosci; 2013 Sep; 56():148-58. PubMed ID: 23659921
[TBL] [Abstract][Full Text] [Related]
8. The relation between α-synuclein and microglia in Parkinson's disease: Recent developments.
Sanchez-Guajardo V; Tentillier N; Romero-Ramos M
Neuroscience; 2015 Aug; 302():47-58. PubMed ID: 25684748
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration.
Qin H; Buckley JA; Li X; Liu Y; Fox TH; Meares GP; Yu H; Yan Z; Harms AS; Li Y; Standaert DG; Benveniste EN
J Neurosci; 2016 May; 36(18):5144-59. PubMed ID: 27147665
[TBL] [Abstract][Full Text] [Related]
10. Infiltrating T lymphocytes reduce myeloid phagocytosis activity in synucleinopathy model.
Sommer A; Fadler T; Dorfmeister E; Hoffmann AC; Xiang W; Winner B; Prots I
J Neuroinflammation; 2016 Jun; 13(1):174. PubMed ID: 27364890
[TBL] [Abstract][Full Text] [Related]
11. Toll-like receptor expression in the blood and brain of patients and a mouse model of Parkinson's disease.
Drouin-Ouellet J; St-Amour I; Saint-Pierre M; Lamontagne-Proulx J; Kriz J; Barker RA; Cicchetti F
Int J Neuropsychopharmacol; 2014 Dec; 18(6):. PubMed ID: 25522431
[TBL] [Abstract][Full Text] [Related]
12. Microbiome-Gut-Brain Axis and Toll-Like Receptors in Parkinson's Disease.
Caputi V; Giron MC
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29882798
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C Virus NS3 Mediated Microglial Inflammation via TLR2/TLR6 MyD88/NF-κB Pathway and Toll Like Receptor Ligand Treatment Furnished Immune Tolerance.
Rajalakshmy AR; Malathi J; Madhavan HN
PLoS One; 2015; 10(5):e0125419. PubMed ID: 25965265
[TBL] [Abstract][Full Text] [Related]
14. Microglia Response During Parkinson's Disease: Alpha-Synuclein Intervention.
Ferreira SA; Romero-Ramos M
Front Cell Neurosci; 2018; 12():247. PubMed ID: 30127724
[TBL] [Abstract][Full Text] [Related]
15. Toll-like receptors in the pathogenesis of neuroinflammation.
Kumar V
J Neuroimmunol; 2019 Jul; 332():16-30. PubMed ID: 30928868
[TBL] [Abstract][Full Text] [Related]
16. Microglia in Parkinson's Disease.
Ho MS
Adv Exp Med Biol; 2019; 1175():335-353. PubMed ID: 31583594
[TBL] [Abstract][Full Text] [Related]
17. Nanomedicine and its application in treatment of microglia-mediated neuroinflammation.
Baby N; Patnala R; Ling EA; Dheen ST
Curr Med Chem; 2014; 21(37):4215-26. PubMed ID: 25039775
[TBL] [Abstract][Full Text] [Related]
18. Neuroinflammation and Glial Phenotypic Changes in Alpha-Synucleinopathies.
Refolo V; Stefanova N
Front Cell Neurosci; 2019; 13():263. PubMed ID: 31263402
[TBL] [Abstract][Full Text] [Related]
19. Innate Immune Surveillance in the Central Nervous System Following Legionella pneumophila Infection.
Lagana P; Soraci L; Gambuzza ME; Mancuso G; Delia SA
CNS Neurol Disord Drug Targets; 2017; 16(10):1080-1089. PubMed ID: 29173188
[TBL] [Abstract][Full Text] [Related]
20. Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson's disease.
Williams GP; Schonhoff AM; Jurkuvenaite A; Thome AD; Standaert DG; Harms AS
J Neuroinflammation; 2018 Aug; 15(1):244. PubMed ID: 30165873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
